BSE Live
Dec 30, 16:01Prev. Close
6389.30
Open Price
6393.10
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 30, 15:56Prev. Close
6390.50
Open Price
6410.00
Bid Price (Qty.)
6360.50 (7695)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Divis Laboratories (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | |||
| SHAREHOLDER'S FUNDS | |||
| Equity Share Capital | 12.82 | 12.82 | |
| Total Share Capital | 12.82 | 12.82 | |
| Reserves and Surplus | 270.84 | 216.38 | |
| Total Reserves and Surplus | 270.84 | 216.38 | |
| Total Shareholders Funds | 283.66 | 229.20 | |
| NON-CURRENT LIABILITIES | |||
| Long Term Borrowings | 3.31 | 6.00 | |
| Deferred Tax Liabilities [Net] | 25.03 | 23.03 | |
| Other Long Term Liabilities | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 28.34 | 29.03 | |
| CURRENT LIABILITIES | |||
| Short Term Borrowings | 62.78 | 59.93 | |
| Trade Payables | 55.45 | 47.91 | |
| Other Current Liabilities | 12.37 | 5.31 | |
| Short Term Provisions | 11.71 | 12.79 | |
| Total Current Liabilities | 142.31 | 125.94 | |
| Total Capital And Liabilities | 454.31 | 384.17 | |
| ASSETS | |||
| NON-CURRENT ASSETS | |||
| Tangible Assets | 181.54 | 166.32 | |
| Intangible Assets | 0.00 | 0.00 | |
| Capital Work-In-Progress | 1.09 | 5.52 | |
| Other Assets | 0.00 | 0.00 | |
| Fixed Assets | 182.63 | 171.85 | |
| Non-Current Investments | 0.01 | 0.06 | |
| Deferred Tax Assets [Net] | 0.00 | 0.74 | |
| Long Term Loans And Advances | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.00 | 0.00 | |
| Total Non-Current Assets | 182.64 | 172.65 | |
| CURRENT ASSETS | |||
| Current Investments | 0.00 | 0.00 | |
| Inventories | 139.05 | 107.60 | |
| Trade Receivables | 102.17 | 86.75 | |
| Cash And Cash Equivalents | 4.49 | 7.19 | |
| Short Term Loans And Advances | 25.96 | 9.98 | |
| OtherCurrentAssets | 0.00 | 0.00 | |
| Total Current Assets | 271.67 | 211.52 | |
| Total Assets | 454.31 | 384.17 | |
| OTHER ADDITIONAL INFORMATION | |||
| CONTINGENT LIABILITIES, COMMITMENTS | |||
| Contingent Liabilities | 5.20 | 10.27 | |
| CIF VALUE OF IMPORTS | |||
| Raw Materials | 64.38 | 55.75 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | |
| Capital Goods | 3.56 | 2.10 | |
| EXPENDITURE IN FOREIGN EXCHANGE | |||
| Expenditure In Foreign Currency | 3.79 | 2.78 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | |||
| Dividend Remittance In Foreign Currency | 0.11 | 0.11 | |
| EARNINGS IN FOREIGN EXCHANGE | |||
| FOB Value Of Goods | 301.59 | 258.72 | |
| Other Earnings | 6.60 | 2.71 | |
| BONUS DETAILS | |||
| Bonus Equity Share Capital | 0.15 | 0.15 | |
| NON-CURRENT INVESTMENTS | |||
| Non-Current Investments Quoted Market Value | -- | 0.05 | |
| Non-Current Investments Unquoted Book Value | 0.01 | 0.01 | |
| CURRENT INVESTMENTS | |||
| Current Investments Quoted Market Value | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- |
20.11.2025
Accumulate Divis Laboratories; target of Rs 6795: Deven Choksey
14.11.2025
Divis Labs Consolidated September 2025 Net Sales at Rs 2,715.00 crore, up 16.12% Y-o-Y
12.11.2025
Neutral Divis Laboratories; target of Rs 6925: Motilal Oswal
12.11.2025
Divis Labs Standalone September 2025 Net Sales at Rs 2,660.00 crore, up 15.55% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill